Furthermore, pretherapy IL-19 levels were significantly associated with lymphedema, general lymphadenopathy, and recurrence (r = 0.426, P < 0.001; r = 0.239, P = 0.035; r = 0.641, P < 0.001) (Table 4). This evidence concerns the gene IL19 and Lymphadenopathy.